Concerto Biosciences’ Post

Concerto loves microbes, and we're not the only ones. Check out this article from the BBC: "Our skin is teeming with microbes. We should learn to love them." When our skin microbes work well together they fight infections, maintain hydration, accelerate wound healing, shield against UV radiation, and train the immune system. When microbes don't, they drive conditions like eczema, psoriasis, dandruff, acne, and even cancer. At Concerto, we show our love of microbes—and the people they live on—by “solving” the microbial ecology governing how microbes interact with each other to keep us healthy and then developing products that harness that power. Learn to love microbes? We couldn't agree more.

On the latest episode of the Building Biotechs podcast, hosted by Carina Clingman, PhD, our CEO Cheri Ackerman shares Concerto’s perspective on building a business through iteration and optimization: All aspects of company creation, including the business model itself, can be treated as experiments. This framework is articulated in one of Concerto’s core values, grow by experimenting. Tune in to hear more about Concerto’s many experiments across business, science, and culture. Cheri also offers valuable fundraising advice and great book recommendations.

Wondering how Concerto thinks about AI, global health, the looming threat of antibiotic resistance, and how the kChip discovery platform fits into all of this? Find out in this feature from Bio.News. https://lnkd.in/eE5hZen6

Let's raise a glass to Concerto’s 4th anniversary as a company. For Gala_004, we gathered for a night of dazzling lights, a live quartet (4 musicians in honor of 4 years, of course), signature microbial cocktails, and absurd, wonderful, collaborative music making (see the pics!). Microbes are the performers of nature’s grandest symphony. We thank everyone—Concertians, advisors, investors, friends—who attended our birthday party to help celebrate them with us.

Drumroll please! Concerto Biosciences has officially secured an open Investigational New Drug (IND) application for Ensemble No.2 (ENS-002) First-In-Human clinical trials. In the biotech world, this is a pivotal moment, not only showcasing our technical rigor, but also representing a huge step toward improving patient lives with microbial treatments. Next stop: the clinic! https://lnkd.in/ek3BTYSk

Concerto will attend #BIO2024 this year as an NIH Innovation Zone Company. Come see CEO Cheri Ackerman’s presentation (Exhibition Hall on Monday, June 3 at 4:30pm PST) on Concerto’s kChip discovery engine and our plans to bring groundbreaking microbial products to the market. CBO Roger Frechette and Senior Director of Biz Dev Didier Vingadassalom, PhD, MBA will round out the Concerto team, available all week for partnering and investor discussions. Set up a meeting in advance through the BIO Partnering Portal or connect via LinkedIn. See you there!

Microbes are the performers of nature's grandest symphony. …and Concertians are composers. In the words of Concerto CSO Jared Kehe, we want to write music "like Beethoven, Mahler, Rachmaninoff composed complex, expressive musical ensembles [where] each instrument plays its role, reacting to the others, informed by and informing the others, and synergizing with the others" (full interview here: https://lnkd.in/etUwgWWb). Let the microbial music play.